Linical H1 Sales Fall 23.0% and Operating Loss Widens to ¥1,280 Million, but Order Backlog Jumps 35.2% to ¥15,780 Million

Linical's net sales fell 23.0% to ¥3,739 million in H1 FY3/2027 and its operating loss widened to ¥1,280 million from ¥511 million, with Japan, the U.S. and Europe all in the red. But delayed large contracts in the U.S. and Europe were signed, lifting the order backlog to ¥15,780 million by November 16, up 35.2% from the end of March.

Linical H1 FY3/2027 earnings summary

Losses widen in all three main regions

Linical Co., Ltd. (TSE: 2183), an Osaka-based contract research organisation that runs clinical trials for drug makers in Japan, Asia, the U.S. and Europe, reported consolidated results for H1 FY3/2027, April 1 to September 30, 2026, on November 16, 2026 under Japanese GAAP. Net sales fell 23.0% to ¥3,739 million and the operating loss widened to ¥1,280 million, with sales down and losses larger in Japan, the U.S. and Europe; Asia grew as Korea returned to an operating profit and Taiwan expanded, while China fell into the red. Foreign-exchange losses took the ordinary loss to ¥1,360 million, and the net loss attributable to owners was ¥1,223 million, or ¥54.18 per share.

The company says funding is moving away from COVID-19 vaccines into oncology, central nervous system and autoimmune disease, areas where it is strong. Large contracts in the U.S. and Europe that had been held up when the U.S. Food and Drug Administration scaled back work during last year's partial government shutdown have now been signed. The backlog was ¥14,199 million at September 30 and ¥15,780 million on November 16, up 35.2% from ¥11,673 million at the end of March; the U.S. rose 76.0% to ¥4,836 million and Europe 81.1% to ¥5,473 million, while Japan slipped 1.9% to ¥3,869 million.

Going-concern events, but cash in hand

Because it has posted operating losses for two consecutive years and again in this half, Linical reports events or conditions that may cast significant doubt on its ability to continue as a going concern, but it judges that no material uncertainty exists, citing revenue expected from the signed backlog and cash and deposits of ¥3,773 million. Net assets fell to ¥2,577 million and the equity ratio to 24.7% from 33.1%. It kept its full-year forecast of net sales of ¥10,680 million, up 23.2%, operating profit of ¥256 million and net profit of ¥180 million, and plans a year-end dividend of ¥8 per share.

Linical Co., Ltd. — H1 FY3/2027 (April 1 – September 30, 2026), Japanese GAAP, consolidated. Balance-sheet rows compare September 30, 2026 with March 31, 2026; guidance and dividend rows are full-year FY3/2027 against FY3/2026. "—" indicates a figure not disclosed.
MetricH1 FY3/2027H1 FY3/2026Change
Net sales (¥ million)3,7394,859−23.0%
Operating profit (¥ million)−1,280−511loss widened
Ordinary profit (¥ million)−1,360−543loss widened
Net profit attrib. to owners of parent (¥ million)−1,223−927loss widened
EPS (¥)−54.18−41.07loss widened
Order backlog (¥ million)14,19911,673+21.6%
Total assets (¥ million)10,42711,999−13.1%
Net assets (¥ million)2,5773,976−35.2%
Equity ratio24.7%33.1%−8.4 pt
FY3/2027 guidance — revenue (¥ million)10,680—+23.2%
FY3/2027 guidance — operating profit (¥ million)256—loss to profit
FY3/2027 guidance — ordinary profit (¥ million)250—loss to profit
FY3/2027 guidance — net profit (¥ million)180—loss to profit
Annual dividend per share (¥)8.008.00unchanged

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.